text:
View related sites
Cambridge English Language Assessment
Why Cambridge English?
Learning English
Teaching English
You are here:
Find out more about the changes to Cambridge English: Movers from January 2018.
Cambridge English: Movers is made up of three papers developed to encourage and motivate young learners. You can see exactly what's in each paper below.
6 parts/ 40 questions
The Cambridge English: Movers Listening test has five parts. Each part begins with one or two examples. Children will hear each recording twice.
About 25 minutes
Part 1
Part 2
Part 3
Part 4
Part 5
The Cambridge English: Movers Reading and Writing test has six parts. Each part begins with one or two examples. For all parts of the Reading and Writing test, children must spell their answers correctly.
Part 6
The Cambridge English: Movers Speaking test has four parts. Children take the test alone with the examiner, but someone they know who speaks their language (like their teacher) will introduce them to the examiner and explain what to do in their own language.


text:
Simplicity 3287; ©1950; Misses' Blouse and Skirt: The front-buttoned blouse has a small Peter Pan collar. A flared panel with an inverted pleat gives back fullness to the otherwise slim skirt. Style 1, blouse, features three-quarter length sleeves with pointed cuffs. The cuffs and collar are of contrasting fabric. Style 2 is sleeveless and double sets of pockets trim the blouse front. Saddle stitching outlines the collar and pockets. Featured in Simplicity Magazine, August 1950
Links to reviews/blog posts Edit
Sources/Vendors Edit
Gallery Edit
[insert your photos of this pattern made up]
Wishlist Edit
[insert your username, and make sure your preferences allow for people to contact you via e-mail. Do not list your email address here!]

subset: commoncrawl


text:
PRESCRIPTION DRUG USER FEE AMENDMENTS OF 2007 -- (Senate - May 09, 2007)
Mr. KENNEDY. Madam President, we will see later this morning the successful conclusion of this legislation. We have some important matters to consider, which we will do in a very short period of time. But as we are coming into the closing time for this amendment, I think it is appropriate that we review very quickly what this legislation does and what it does not do.
I am a strong believer in this legislation, which has strong bipartisan support. I am enormously grateful to Senator Enzi and Members on our side of the aisle as well as those on the other side for all of their help and assistance in getting us to the point where we are ready to take final action on something that makes a major difference to families in America. We ensure the safety of our prescription drug system and also are making very important progress in the safety of our food supply.
This is, in an important way, breakthrough legislation. I will review quickly what this does and then come back to the amendments that are before the Senate and how we think the Senate should dispose of them; why this legislation is urgent, why it is extremely important, and why the American people deserve the best.
Very quickly, again, there is strong emphasis on safer food and safer medicines for families in this country. We spelled out at the earlier part of our presentations the effective systems we have supported to make sure we are going to have the safest prescription drug program in the world, using different kinds of modern technologies and also modern surveillance systems for monitoring postmarketing safety. This will ensure in the future we are going to have the safest prescription drug program in the world. We will have safer medicines.
We will also have safer food for families and pets. I think all Americans have been alarmed, as they should have been, by what has been reported in the news in the last few weeks. Many families have lost their pets because the agency lacked the
authorities provided in this bill.
We will have earlier warnings on drug safety problems using extremely elaborate systems of postmarketing surveillance. These systems will use both public and private centers to collect information that the FDA will use to find early warnings of possible harm. In these cases, the agency will be able to take expeditious action. That has never been done before.
We are going to have better medicines for children. We are enormously appreciative of the excellent work that has been done by Senator Dodd and Senator Clinton. This was done in a bipartisan way with Senator DeWine, who is not here. We all realize that children are not little people; children are children, and therefore their bodies react differently to various kinds of prescription drugs. This legislation provides mechanisms to get information on safe and effective use of medications in children as well as to promote studies of drugs in pediatric populations. In the past few years, we have made enormous progress and we believe this legislation will help to an even greater extent.
We are going to have more transparency and stronger science at the FDA because of the wonderful work done by Senator Mikulski. She and others worked to assure that we have greater awareness by the public of what is happening at the agency.
There is greater focus and attention on making sure the agency is going to have the best in terms of the new sciences. We are in the life science century at the present time. This has been impressed on the country with the extraordinary convention on biosciences that took place in Boston in the last few days. There I listened and read about the potential the life sciences have, not only in terms of energy and agriculture but also in terms of medicines. The United States is absolutely poised to continue to be the world leader in these fields, with all of its implications of healthier families here and around the world.
We need to make sure we are going to have the best kind of science at the FDA. We do that in the way we have given greater authority over the development of the science function at FDA. We also provided a rather unique foundation that will be able to use public and private funding. This foundation will seek out the best and the newest modalities to help speed the review of various prescription drugs. That is going to be enormously important because time means cost. If we are able to resolve these issues more quickly the costs will be more understandable and reasonable to consumers and we will get them faster.
Briefly to comment on some of the amendments, we have taken a position in our proposal that both the safety and efficacy of particular prescription drugs is a function that ought to be considered in tandem. I know there are those who think we ought to separate those functions. We can imagine a circumstance, for example, where the side reaction of a particular drug is that individuals lose all of their hair and they become nauseated. Clearly I am describing the impact of methotrexate. That can happen to an individual on many anticancer drugs. You wouldn't prescribe that for athlete's foot because the side effects are so dramatic, but you would approve that for another kind of regime to try to treat cancer.
We also have items on civil penalties for the first time. There is a question of what those civil penalties should be. I want them to be higher, but I am mindful as well that this is the first time we are going to have those civil penalties. We are going to be working on those matters with the House. I basically think they should be a little higher, but I listened to my colleague on this issue and we are going to try to make sure we get something that is going to be fair and can do the job.
I am also mindful of the concern we have in terms of the potential of conflicts of interest. I will reserve my time to be able to deal with this issue.
This is a very important issue. We want to make sure, on the one hand, as we have these breakthroughs in science, that we are going to have the best experts participating in these review groups. We also have to be sensitive to the issues of conflicts of interests. I know the Senator from Illinois has a proposal on this.
I will reserve the rest of my time to be able to discuss that later.
Mr. KENNEDY. Madam President, I would like to take some time to talk about some issues that I haven't spent a great deal of time describing to the Senate about S. 1082, the Food and Drug Administration Revitalization Act.
First, I thank Senator Roberts and Senator Harkin for working with Senator Enzi and me and with many members of the committee on the important issue of direct-to-consumer, or DTC, advertising.
We have worked together to accomplish our common goal--a constitutionally sound, effective, workable way to see that DTC ads provide accurate information to patients about the drugs they are taking.
Some have advocated a ban on such advertising altogether, but Senator Enzi and I rejected that approach since it failed to meet the constitutional test. Instead, we included a more measured provision in our legislation that allows FDA to impose a moratorium in extraordinary circumstances where needed to protect public health.
During our committee's consideration of this issue, Senator Roberts brought up his concerns that even this limited provision fell afoul of recent Supreme Court decisions on free speech. Senator Harkin raised his strong interest in seeing that these DTC ads include strong, effective safety information that is clearly and prominently presented to consumers in a way that does not gloss over important information. Senator Enzi and I committed to work with Senator Roberts to see that any provision on DTC met the constitutional threshold, and we agreed to work with Senator Harkin to make certain that it provided strong safety information to consumers. The result of our discussions is an amendment that our two colleagues offered. It is a true bipartisan compromise, worked out by two Senators committed to making real progress on an important issue, and I am pleased to support the amendment.
Instead of the moratorium included in our original bill, the Roberts-Harkin amendment puts in place strong safety disclosures for DTC ads, coupled with effective enforcement. Under current law, safety disclosures can be an afterthought--a rushed disclaimer read by an announcer at the conclusion of a TV ad while distracting images help gloss over the important information provided. Our proposal requires safety announcements to be presented in a manner that is clear and conspicuous without distracting imagery.
We also give FDA the authority to require safety disclosures in DTC ads if the risk profile of the drug requires them. Senator Roberts had a concern that this authority not be used indiscriminately, so we have made clear that the required disclosure must pertain to a specific identified risk.
We have made important improvements in FDA's ability to enforce the requirement to provide clear and accurate information to consumers.
For advertisements, as in so many other areas, FDA's enforcement tools are now limited. Although FDA does have the capacity under current law to remove a drug from the market for misleading ads, that authority is not often used and rightly so, since it punishes patients for the transgressions of the manufacturers. Since removing a drug from the market is an empty threat, FDA is often left with little option but to make polite requests to companies to change their ads. Under the Roberts-Harkin amendment, FDA will have the ability to levy fines of up to $150,000 for false or misleading ads.
It is unacceptable for patients to be put at risk by inaccurate ads. The Roberts-Harkin amendment makes certain that FDA will have the ability to see that this does not occur, in a way that is clearly consistent with the Constitution.
The amendment is a victory for bipartisan common sense on a difficult issue.
I would also like to address the affect of title II of this bill. Generally speaking, title II grants the FDA new authority to conduct postapproval safety surveillance activity in order to improve drug safety.
In enacting title II, we do not intend to alter existing State law duties imposed on the holder of an approved drug application to obtain and disclose information regarding drug safety hazards either before or after the drug receives FDA approval or labeling. Nor are we expressing a belief that the regulatory scheme embodied in the bill is comprehensive enough to preempt the field or every aspect of State law. FDA's approved label has always been understood to be the minimum requirement necessary for approval. In providing the FDA with new tools and enhanced authority to determine drug safety, we do not intend to convert this minimum requirement into a maximum.
As the Institute of Medicine and others have found, the FDA's past performance has been inadequate. While we fully expect substantial improvement as a result of the enactment of this bill, we cannot and do not expect the FDA or this new process to identify every drug-specific safety concern before a drug manufacturer becomes aware or should have become aware of such concerns. Nor are the bill's requirements that holders disclose certain safety information to the Government intended to substitute for the disclosure requirements that may be required under State law.
I would also like to focus on another aspect of our legislation, the Reagan-Udall Foundation.
During the discussions that led to consideration of this bill, we heard time and again that there was a major need for better research tools to aid FDA in evaluating the safety of drugs and help researchers move through the long process of developing drugs more effectively. Every day that a new medicine is needlessly delayed is another day that a patient does not receive a treatment that could well mean the difference between health and continued illness. If new research tools and better ways to evaluate the safety and effectiveness of drugs could be developed, patients will benefit from quicker drug development. If current procedures can be made more effective, then the cost of developing new drugs will drop.
One area where scientists can make real progress is developing new cell lines and new genetic techniques for testing drugs that reduce the need for costly forms of testing.
The Reagan-Udall Foundation sets up a way to develop these new tools--not so they can help just one researcher or one company, but so they can help the entire research enterprise. New ways to test drugs for effectiveness and safety will bring new advances to patients quicker and more smoothly. Through the Reagan-Udall Foundation, they will be available to the FDA and to the entire research enterprise. This new foundation is not many pages in a long bill, but it is an important component to help get needed medicines to patients as quickly as safety will allow.
I also wish to mention another critical aspect of our legislation--its registry of clinical trials.
This provision serves two essential purposes. First, it allows patients who want to enroll in those trials an accessible and central Internet site to find out which trials are being conducted and whether they might be eligible.
This provision builds on an existing provision of law to create a clinical trials site, but report after report has shown that the requirement to list trials has not been complied with. Our legislation puts more force in the requirement to list trials so that patients will benefit.
Listing trials is important for patient access--but reporting results is critical for safety. Our legislation requires that the results of trials be reported. No longer will companies be able to hide the outcome of a trial that did not turn out the way they hoped.
Examples of this kind of abuse are shocking. The manufacturer of the antidepressant drug Paxil conducted five clinical trials of the drug in adolescents and children, yet published only one study whose mixed results it deemed positive. The company sat on two major studies for up to 4 years, although the results of one were divulged by a whistleblower and all of the studies were submitted to the FDA when the company sought approval for new uses of Paxil. At that time it became apparent that Paxil was no more effective than a placebo in treating adolescent depression.
Under the bill, these kinds of abuses will not be permitted, since clinical trials will have to be reported--no matter what the result.
Senator Enzi, Senator Dodd and many others in the committee worked hard to get this provision right. We require immediate listing of all publicly available data and require a negotiated rulemaking, backed by the full authority of statute to develop the precise requirements for other results information to be included.
I would like to thank my colleagues for considering these comments as they relate to S. 1082, and I urge my colleagues to support the bill.
Mr. KENNEDY. Madam President, I commend my colleague from Illinois and my colleague from New Mexico for their amendment on the conflicts of interest and for working with us to address these issues in appropriations bills during the past year.
Their amendment includes many thoughtful proposals I support: including the right to call for the FDA to improve its outreach to experts who have no conflicts of interest and their right to call for greater transparency in the process of waivers.
But where I disagree with my friend from Illinois and New Mexico is that there should be an inflexible cap on the number of waivers for conflicts of interests an advisory committee can grant, no matter what the expertise of the scientists involved.
The amendment would impose a one-size-fits all, one waiver per conflict, per committee, relegating any additional members with conflicts to a secondary guest status on the committee.
The FDA has recently issued a policy not to grant a waiver for a financial interest that exceeds $50,000 and will allow those who receive a waiver for a lesser conflict to serve only as members who can participate in committee discussions but not vote.
The hallmark of this proposal is the flexibility it gives to ensure the committees will have the adequate expertise. If one or more experts with financial conflicts in excess of $50,000 have expertise that is essential to a committee, the Commissioner can grant the needed waivers. This is expected to be rare, but it can happen if needed.
Under the Durbin amendment, by contrast, the FDA can grant only one waiver per meeting. There is no flexibility on this point.
The FDA is already experiencing difficulty in filling vacancies on advisory committees. The Durbin amendment, no matter how well-intentioned, would worsen the problems, making it harder to fill critical vacancies and slowing the process of reviewing new medicines.
Let's look at the problem FDA is facing now. The Antiviral Drugs Advisory Committee needs six experts with specialized knowledge in the fields of clinical pharmacology, internal medicine, infectious diseases, microbiology, virology, immunology, pediatrics, and other specialties. These experts are needed to review the safety and effectiveness of new medicines for pandemic flu, HIV/AIDS, and other serious infections. The Anesthesiology and Respiratory Therapy Devices Panel has nine vacancies. The Ophthalmology Panel is in need of nine experts. The Advisory Committee on Peripheral and Central Nervous System Drugs needs six members--on and on down the list, the story is the same, critical vacancies, missed opportunities, and missed expertise. I am not for conflicts of interest. I am against them. But they are a fact of life.
We need policies that reflect the current reality of research in the life sciences. We have increased transparency in this legislation so there will be wide understanding of exactly how decisions are made. This is the most important. In the time of life sciences, we are talking about cross-fertilization of different ideas. Visit the Institute of Medicine. They are talking about the life sciences and work that is taking place. Flip a molecule and it could be relevant to alternative fuels. Flip it again and it can be relevant to agriculture. Flip it again and it can be relevant to the health sciences. We need all of these disciplines working together. To take one particular requirement and exclude the possibility of getting the best in terms of future scientists, we need integrity in the FDA, integrity in decisionmaking, integrity when they grant waivers. The public ought to have the right to know. We have a balance in here. Hopefully, we will retain it.
I withhold the remainder of my time.
Mr. KENNEDY. Mr. President, I yield myself 5 minutes.
I support the comments Senator Enzi has made about the fines. We are going to have to look at this in conference, and it is clear the House is going to raise the fines, it seems to me, as Senator Enzi pointed out. So we will have a chance to look at it in conference. I think that is probably the best way to do it.
Let me point out two other items--something I think most Americans have been concerned about in recent times. It was reported today that China has detained managers from two companies linked to contaminated foods. As a first step, we need to determine the extent of the contamination and see how far into the food supply this internal adulteration has gone.
Yesterday's report from the FDA that contaminated wheat flour from China was fed to fish raised for human consumption is another example of the need for a comprehensive examination of our food safety system. We also found out yesterday that what we thought was contaminated highly processed wheat gluten was actually unprocessed wheat flour spiked with melamine to make it appear to be higher quality.
A month ago, the FDA warned that certain types of pet food were suspected of being contaminated. Then, there were more kinds of pet food. Then it was hogs being fed the contaminated food, but those had been caught before human consumption. Then we found out that tens of millions of chickens eaten by people had been fed the tainted food. Yesterday, we were informed that fish raised for human consumption had been fed contaminated food.
The incremental expansion of this crisis raises serious concerns about the FDA's ability to rapidly identify the source of food-related problems and bring to bear the effective tools. We know the issue of food safety is divided into different kinds of committees, but it has to be of concern to American families.
We have included strong new protections to allow FDA to better ensure the safety of human and pet foods, but this is a first step. Senator Enzi and Senator Durbin have joined with me and others and we are committed to taking a comprehensive look at the safety of our food supply and we are committed to taking the actions, with our colleagues, needed to ensure that the foods our families and pets eat are as safe as possible.
As part of the managers' package adopted last night, we included important new provisions to allow the FDA to oversee the safety of farm-raised fish. We owe this--this is a story in the paper today--to Senators LINCOLN and PRYOR and SESSIONS on this important proposal.
This morning's newspaper talks about doctors reaping millions for the use of anemia drugs. People are going to wonder what we are doing in this bill, if anything, on this issue. Well, this is not what the FDA does exactly. It is safety and efficacy. But there are different agencies in what they call health research and quality. AHRQ has responsibility for this. We will be in touch with them to examine this issue and provide better guidance and recommendations to doctors and patients.
The FDA does not practice medicine. But this kind of action has to be of concern because it reflects itself in increased costs to the American consumer, and it does raise health issues as well.
So this is illustrative of the range of different areas of concerns the American families have. We believe we have made very important and substantial progress in trying to address those questions.
Mr. President, at this time I will withhold the remainder of my time.
Mr. KENNEDY. Mr. President, in a few minutes, we will be prepared to vote. I yield myself 3 or 4 minutes.
I will include in the Record, at the conclusion of this debate, the names of the staff on our committee who have done superb work. It has been extraordinary and on both sides of the aisle. We are enormously appreciative and grateful.
I am also personally appreciative of the work of my friend and colleague, the Senator from Ohio, Mr. Brown, who was here yesterday and filled in. I had the opportunity to travel to Ireland, where they signed and put in place, after 400 years of struggle, the democratic institutions over there, in a very moving ceremony, which President Bush had supported--a very special day.
This legislation is a reflection of 2 1/2 years of hearings under the leadership of Senator Enzi, when he was chair of the committee, and myself. It incorporates the Institute of Medicine's recommendations, by and large, after they had months and months of hearings. The American people ought to understand the legislation, which reflects bipartisan support in the Senate, is a reflection of the best judgments we could have as a result of months and years of working on this issue and of the membership on it. We are enormously grateful.
This legislation is going to make the prescription drugs our families take safer and our food safer. That is very important. It is going to ensure that the Agency has resources to do follow-on reviews to continue its important function to be the world leader, the gold standard, for safety for our people and the example for the rest of the world. So this is very important legislation.
We are reminded every day of the additional kinds of challenges we are facing in terms of safety for our families. We are very aware of it. Senator Enzi and I and the members of our committee are going to continue our study, our review, and continue our activity to ensure we are going to have the best in terms of a safe and secure food supply, pharmaceutical supply, and take advantage of this life science century so every American is going to have the best and, hopefully, at the most reasonable price, so they can have healthier and stronger families.
Mr. KENNEDY. Mr. President, the FDA has a new policy, a new procedure out there.
Basically, what the Durbin amendment says is, one size fits all. That concept has been rejected by the Europeans, rejected by the Canadians, and basically rejected by the Institute of Medicine. In this life science century, researchers who are looking at cancer drugs may be examining 15 different components. Are we going to say that if a conflict exists with one of those components that they meet the Durbin amendment standard. This would exclude some of the most knowledgeable people in this country from participating in the review of breakthrough drugs.
The FDA says they have adopted transparency. Everyone in the Senate is going to know who sits on the advisory committees. There is a financial limitation of $50,000 at the FDA now. Everyone is going to know the existence of any conflicts. It is a new day out there. We have now have transparency, but virtually everyone who understands that we are in the life science century says we have to have the best scientific minds at the table, and so the Institute of Medicine said: Don't go with a one-size-fits-all, which the Durbin amendment does.
Mr. KENNEDY. Mr. President, one of the great joys of serving in the Senate has been working with my friend and colleague from Wyoming, Senator Enzi, on different legislation. He does it the old-fashioned way. He believes that what we ought to do is have the hearings on the problem and then listen to various alternatives and then try to work out a solution and carry the process forward. That is the old-fashioned way. Today people look at different issues, file bills, and try and ward off interventions. He has a deep-seated conservative philosophical commitment. He and I differ on some matters, but we always try to find common ground. We have been able to find it certainly on this legislation and many other pieces of legislation. I look forward to continuing this tradition. I am personally grateful to him for all his help in guiding us. You can see the closeness of these votes. This is enormously important legislation to bring the Food and Drug Administration into the 21st century. But there are strong feelings, strong opinions, strong arguments on different ways to do so. We have legislation. It is solid legislation. We are proud of it. I think the overwhelming, virtually unanimous vote of the Senate on both sides is a vindication of the efforts our committee has made. It starts with Senator Enzi. I am grateful to him.
I see Sherrod Brown, the Senator from Ohio, was kind enough yesterday to stand in for me when I had the great honor to witness the coming together in Northern Ireland after 400 years of conflict and the establishment of democratic institutions in a very momentous historical moment. When I left Monday night, there was a certain element of chaos surrounding this bill, and coming back early this morning, under the great work of Senator Enzi and Senator Brown, we had an orderly path to proceed. He is knowledgeable about health issues and had a very distinguished record on health policy before he came to the Senate. He has not missed a beat in working through the issues. He has been invaluable to me personally and to our committee. I thank Senator Brown for all of his good work.
Quickly: I would like to thank my friend, Senator Dodd for his work on all of the issues that affect kids' drugs and devices; Senator Clinton for her work on drugs and devices; Senator Mikulski for her work on the issues of transparency, enormously important provisions on which this legislation depends; Senator Hatch for his work on antibiotics; Senator Gregg for his work on the databases and Web portal; Senators ROBERTS and HARKIN for their work on the direct to consumer advertising issue, which involves a lot of different policy issues and a lot of emotion and feeling. They worked very hard with the staff, we had very solid recommendations on this; Senator Stabenow for her work on the citizens' petitions in order to help get product onto the markets in a quicker way. I would also like to thank Senator Brown and Senator Brownback, for their enormously creative innovative idea with regard to neglected diseases. This is something the United States should be doing more of, and they have been very creative in coming up with an idea; Senator Coburn on the doctor-patient relationship, a subject matter he feels intensely about and has been helpful to us on the legislation; Senator Durbin on food safety provisions, very important and helpful; Senator Alexander on the children's drugs; Senator Allard on food safety issues; Senator Lincoln on food safety including the raised-fish issue.
These are some of the items. Again, we thank staff members: From my staff, Dave Bowen, David Dorsey, David Noll, and Caya Lewis, all who have spent a great deal of time and effort over these past weeks, Michael Myers and Carmel Martin and Missy Rohrbach, Tom Kraus, I thank them enormously.
I express appreciation to Senator Enzi's staff. If people try to find solutions, rather than perpetuate differences, it makes an enormous difference. That was certainly true of all the staffs on our committee. I thank Amy Muhlberg and David Schmickel and Keith Flanagan and Katherine McGuire, Shana Christrup; Senator Brown's staff: Ellie Dehoney; Senator Dodd: Tamar Magarik; Senator Mikulski: Ellen-Marie Whelan; Senator Hatch's staff: Patty DeLoatche, and Trisha Knight; Mike Woody from Senator Harkin; Senator Gregg: Liz Wroe; Senator Roberts: Jennifer Swenson, Mike Seyfert, and Kate Anderson; Senator Clinton's staff: Ann Gavaghan and Andrea Palm. I am sure I might have missed someone, but we will make sure they are included in the RECORD.
We thank all our colleagues and friends. We look forward to meeting with the House and reflecting the Senate's best judgment on the legislation.
Mr. President, over the past 10 days we have had a good debate about important issues affecting the safety of our Nation's citizens, about the drugs they use when they are ill, and about the food they eat every day.
S. 1082 will reauthorize two important user fee programs at the FDA. First among these is the prescription drug user fee program. In 2008, the program is projected to supply the FDA with nearly $400 million to help support new drug reviews and monitor the safety of drugs once they are approved and on the market. Additionally, the bill will reauthorize the medical device user fee program, which subsidizes the medical device review process. Both these programs speed new medical products to patients by enhancing the resources the FDA can devote to medical product review, without changing the standards that must be met for FDA approval or clearance.
These resources to enhance speedy access to drugs and biologics are balanced with several significant provisions that will improve postapproval drug safety. A public-private partnership involving the FDA will build a network of health care databases to gather far better information about the safety risks of prescription drugs. Expanded drug user fees would also be used to develop this active surveillance system for all FDA approved drugs.
The bill will create an additional risk-based method for approving and monitoring new drugs and biologics, called risk evaluation and mitigation strategies, or REMS. A REMS consists of a flexible collection of tools that the agency can apply to address the unique risks associated with a new drug. From labeling changes to postapproval safety studies to measures to assure safe use of a drug, the bill gives FDA important new authorities to address safety issues that arise after a drug is approved. For the first time, civil money penalties will deter noncompliance. The bill increases drug user fees to implement the REMS and enhance the postapproval drug safety system.
Furthermore, this legislation would improve transparency, strengthen the agency's science-based culture, and inspire the trust of the American public. For example, it would require the FDA to identify and disclose conflicts of interest among advisory committee members who provide the agency expert scientific recommendations.
It would also improve access to information for patients and health care providers by launching a pubic database with the results of clinical trials. A clinical trials registry would enhance patient enrollment and provide a mechanism to track the progress of clinical trials.
Finally, the legislation would establish the Reagan-Udall Foundation for the FDA to head collaborative research projects, among the FDA, academic institutions, and industry intended to improve medical product development and evaluation.
I appreciate Senator Dodd and Senator Clinton's leadership to promote the safety of drugs and devices used to treat children.
I thank Senator Roberts and Senator Harkin for working with Senator Enzi and me to design constitutionally sound, effective, and feasible controls on DTC advertising. The amendment we produced will ensure the information that ads provide is accurate, clear, and conspicuous without imposing a moratorium.
I commend Senators Stabenow, Brown, Lott, Thune, Coburn, and Hatch for coming to a solution on the issue of citizens' petitions. They were able to craft an amendment that ensures that only citizens' petitions with meritorious claims could delay approval of a generic drug and that frivolous petitions will not lead to unwarranted delays in the approval of new generic drugs.
I applaud Senator Brownback and Senator Brown for their novel proposal to encourage investment in new medicines for neglected tropical diseases. Their proposal entitles companies that develop new therapies or vaccines to a voucher allowing them a priority review at the FDA for a product of their choosing. It would provide pharmaceutical manufacturers a significant incentive without raising costs to consumers or relaxing the safety standards applied to the drug given priority review.
I would also like to draw attention to the essential amendment introduced by Senator Hatch, with important contributions from Senators Brown, Burr, Stabenow, and others. The amendment would close a loophole that did away with the incentive to bring old but never approved antibiotics to market. It would also establish a public process to identify drug-resistant infections that are orphan diseases and that could be treated with orphan drugs. Additionally, the amendment would make certain molecules that are a part of old active ingredients eligible for recognition as new active ingredients, provided they will be used for a new indication. This provision includes limits that would prevent pharmaceutical manufacturers from abusing the process to extend the life of old active ingredient drugs.
Finally, I am grateful to my friend, Senator Enzi, for his leadership and commitment to addressing prescription drug safety. We have worked together for over 2 1/2 years to develop this legislation, and I am proud of where we are today.
I have already thanked a number of people, and I would also like to thank, on Senator Enzi's staff, Ilyse Schuman, and on my own staff, Stacy Sachs, Molly Nicholson, Jeff Teitz, and Charlotte Burrows, and two of my interns, Ashley Bennett and Lara Mounir.
I would also like to thank the many other staff members, both on and off the committee, who did such great work on this bill: Carmen Green, Nancy Hardt, Paula Burg, Lisa German, Jessica Gerrity, Dora Hughes, Ed Ramos, Ben Klein, Jim Esquea, David Lazarus, Lisa Layman, Jenny Ware, Mary-Sumpter Johnson, Stephanie Carlton, and Jennifer Claypool.
I would also like to thank the legislative counsels Bill Baird, Amy Gaynor, and Stacey Kern-Scheerer for all of their hard work on this bill.
Source: http://thomas.loc.gov


text:
A New York elementary school is in hot water after African American fifth-graders were told to "sit with white kids" or else they will look like a "gang in the hood."
The statement was made by an employee at the upstate New York school, which is now under investigation by the school district.
The employee has not been identified, nor has her position. She has only been noted as a member of the Catskill Elementary staff, according to the Catskill Daily Mail.
Jordan explained that she was disturbed and saddened when she heard about the incident.
She complained to school officials, but all they would tell her was that the situation was "being handled."
The staff member has not even been placed on administrative leave, Jordan says.
Just seeing her at school upsets her daughters, she says. Her daughter now feels like "her white friends [won't] still like her," after word got around that she was supposedly "excluding" them.
Catskill Superintendent of Schools Kathleen Farrell says that they are close to concluding their investigation.
"The building administrators have met with all the students and the parents, and the students were also provided with social worker and guidance staff counseling," Farrell said.
So far, that's all they are saying – and all they are doing. Apparently this is the sort of treatment the Catskill Elementary School thinks African American children are to be subjected to.
This is what systemic racism looks like.
(Article by S. Wooten and M. David)


text:
Efficacy and Safety of a Fixed or a Flexible Supplementary Insulin Therapy in Type 2 Diabetes
This study has been completed.
Novo Nordisk A/S
Information provided by (Responsible Party):
Novo Nordisk A/S
ClinicalTrials.gov Identifier:
First received: January 9, 2006
Last updated: November 20, 2014
Last verified: November 2014
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
This trial is conducted in Europe. This trial aims for a comparison of the efficacy and safety of Insulin Aspart, given in a fixed or in a flexible supplementary insulin therapy, with or without Insulin Detemir plus Metformin, if needed, in subjects with type 2 diabetes.
|Diabetes Diabetes Mellitus, Type 2
|Drug: insulin detemir Drug: insulin aspart
|Phase 4
|Study Type:
|Study Design:
|Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
|Official Title:
|Efficacy and Safety of Insulin Aspart in a Fixed or Flexible Supplementary Insulin Therapy Regimen, With or Without Insulin Detemir in Type 2 Diabetes
Resource links provided by NLM:
Drug Information available for: Insulin Insulin human Insulin aspart Insulin detemirU.S. FDA Resources
Further study details as provided by Novo Nordisk A/S:
Primary Outcome Measures:
- HbA1c [ Time Frame: after 52 weeks ]
Secondary Outcome Measures:
- Blood glucose profiles
- Percentage of patients with HbA1c less than 7.0% after 52 weeks
- Quality of Life
- Frequency of BG measurements
- Safety parameters
- Duration of education
|Study Start Date:
|September 2005
|Study Completion Date:
|November 2006
|Primary Completion Date:
|November 2006 (Final data collection date for primary outcome measure)
|Ages Eligible for Study:
|18 Years and older (Adult, Senior)
|Sexes Eligible for Study:
|Accepts Healthy Volunteers:
Inclusion Criteria:
- Type 2 Diabetes for more than 6 months
- Treatment with 1 or more oral anti-diabetic drugs or insulin, or a combination of these for more than 3 months
- Body Mass Index (BMI) less than or equal to 40 kg/m2
- HbA1c 7.0-11.0%
Exclusion Criteria:
- Treatment with short acting insulin(s) for longer than 10 days
- Current treatment with TZDs. A TZD medication must be stopped at least 14 days before the randomization
- Proliferative retinopathy or maculopathy requiring acute or laser treatment within the last 6 months
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00274274
Please refer to this study by its ClinicalTrials.gov identifier: NCT00274274
|Düsseldorf, Germany
Sponsors and Collaborators
Novo Nordisk A/S
|Study Director:
|Global Clinical Registry (GCR, 1452)
|Novo Nordisk A/S
More Information
Additional Information:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on August 23, 2017
Additional Information:
|Responsible Party:
|Novo Nordisk A/S
|ClinicalTrials.gov Identifier:
|NCT00274274 History of Changes
|Other Study ID Numbers:
2005-000319-87 ( EudraCT Number )
|Study First Received:
|January 9, 2006
|Last Updated:
|November 20, 2014
Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Insulin, Globin Zinc
Insulin Aspart
Insulin Detemir
Hypoglycemic Agents
Physiological Effects of Drugs
ClinicalTrials.gov processed this record on August 23, 2017


text:
Hipstory | Santa Claus Poster/Coaster
More Stunning Ideas - click here >>
We would love to hear from you:
For any questions, comments, feedback or simply drop a line, please contact us at: firstname.lastname@example.com
Want to socialize with us?
You may Tweet to us @bellakoola, post a message or Like us at Facebook.
Hipstory Collection | Amit Shimoni
Israeli artist Amit Shimoni created this great series, depicting global political icons in the
most improbable way possible, outfitted and styled in the latest hipster fashions.
In Shimoni's world, JFK has a nose ring and a Johnny Depp goatee and 'stache.
Gandhi is, of course, a bespectacled, tie-dye-loving hippie, and Abraham Lincoln seems to
be some sort of jewelry-clad bottle service promoter.
This great Santa Claus print with Shimonis' humorous hipster makeover comes on
a high quality wooden coaster, and wall poster.
Size: Coaster: 9 x 9 cm / Wall Poster: 29 x 29 cm
Material: Coaster: Laminated wood / Poster: Gallery quality art print on paper
Color: Multi Color
Sold as: 1
Shipping - World Wide
$0 - $25.00 purchase


text: Warning: mysqli::mysqli(): (HY000/1044): Access denied for user 'admin_global'@'localhost' to database 'admin_energetica21_test' in /home/admin/domains/energetica-international.com/public_html/xpanel/require/mysql/config.php on line 46 Renewable energy > Hydropower | Latest news from Europe Enewsletter subscription for free! Magazines | Enewsletters | Articles | Interviews | Companies Guide | Advertising | Agenda Select your location africa asia pacific cis region europe latinamerica mena & turkey northamerica Business CCS & Emissions Trading Climate Change & Environment Conventional energy Energy efficiency Energy Storage Gen Sets Investment & Financing Other Energy Applications Policies & Regulations Power R&D Renewable energy Solar PV Concentrated Solar Thermal Solar Wind Power Biomass Geothermal Hydropower Ocean Energy Hydrogen / Fuel Cells Other Renewables Smart Grid / T&D Training & Education News from Europe Posted by Gisela Bühl | 2013-08-08 A boost for SolarWorld?s business At an extraordinary general meeting in Bonn, Germany, more than 91 percent of SolarWorld's shareholders voting agreed to implement capital measures to restructure the company's financial position and balance sheet. On Aug. 5 and 6, more than 99 percent of voting... Continue reading >> Posted by Gisela Bühl | 2013-08-06 18% efficiency guarantee in multi-crystalline cells and 20% for mono-crystalline cells The SCHMID Group's 5500 Series APCVD conveyor furnace a well-proven system is available for the industrial mass production of highly efficient cells already on duty in specific application domains, such as is the preparation of doped glasses in the semiconductor industry. Dr.... Continue reading >> Posted by Gisela Bühl | 2013-08-06 Four solar power plants completed and sold on Sardinia REC, has developed, constructed, financed and sold four solar power installations in Villacidro (4,986 kW), Pischedda (996.4 kW), Ulmos (901.6 kW) and Lula (990 kW) on Sardinia, making a total capacity of 7.87 MW. The four ground-mounted solar plants have been sold... Continue reading >> Posted by Gisela Bühl | 2013-08-01 Residential photovoltaic (PV) energy storage systems boom expected according to IHS The market for residential photovoltaic (PV) energy storage systems is expected to boom in the coming years, with cumulative installations amounting to 2.5 gigawatts (GW) by 2017, equivalent to the solar power that could be generated by more than 600,000 homes. Kick-started... Continue reading >> Posted by Gisela Bühl | 2013-07-31 Hanwha Q CELLS to reach solar energy package customers through OBI stores in Germany In the framework of a new cooperation, OBI and Hanwha Q CELLS are launching an extensive solar energy package for home owners interested in installing a photovoltaic (PV) rooftop system. Effective immediately, the Hanwha Q CELLS PV kits are available in selected OBI stores in Germany. The... Continue reading >> Posted by Gisela Bühl | 2013-07-31 meeco Services Hellas finalizes a new grid-connected PV project in Oropos meeco Services Hellas S.A., the fully-owned Greek subsidiary of the Swiss-based meeco Group has finalized yet another ground-mounted photovoltaic (PV) project. This turnkey PV installation is located in Oropos, a town situated in the municipality of East Attica,... Continue reading >> Posted by Gisela Bühl | 2013-07-31 Safety and power-output performance of PV modules through thresher test TÜV SÜD's Thresher Test provides robust information on the safety and power-output performance of PV modules in the long term. The first certificates were issued to three leading Chinese solar module manufacturers. "Conventional certification of PV... Continue reading >> Posted by Gisela Bühl | 2013-07-26 Austrian crystalsol signs agreement to produce its flexible PV film for integration in building elements crystalsol announced the signing of a production partnership with Forster Verkehrs- und Werbetechnik GmbH. Forster will produce crystalsol's flexible photovoltaic film for integration into building elements. Forster's commitment reflects the promising market... Continue reading >> Posted by Gisela Bühl | 2013-07-26 Two contracts for Meyer Burger in UK and Taiwan Meyer Burger Technology announced the successful signing of an important new contract as preferred supplier with Sunsolar Energy Ltd, the first UK domestic module manufacturer, to deliver the very first automated, integrated module line in the United Kingdom for the production of high... Continue reading >> Posted by Gisela Bühl | 2013-07-19 Innovative inspection system for the detection of micro cracks in processed solar cells Today's major challenges in photovoltaic production are the optimization of solar cell efficiencies and the reduction of manufacturing costs. ISRA VISION provides a complete range of state-of-the-art high-precision inspection systems that enable PV manufacturers to master these... Continue reading >> Posted by Gisela Bühl | 2013-07-18 17-year loan achieved to finance one of Thuringia's largest thin-film solar PV parks Masdar PV, which manufactures thin-film solar photovoltaic (PV) modules, has secured a 17-year loan to finance one of Thuringia's largest thin-film solar PV parks. The lending consortium led by Ostsächsische Sparkasse Dresden and the Sparkasse Gotha provided the loan. The... Continue reading >> Posted by Gisela Bühl | 2013-07-17 Microinverters the ideal option for residential solar power Micro inverter technology is widely regarded as one of the most promising ways to attract residential investors to solar power. The technology generates more yield, reduces installation costs and lasts longer than string inverters. One of the largest manufacturers of... Continue reading >> Posted by Gisela Bühl | 2013-07-09 Plastic PV mounting systems impeccably stable after 15 years of use The ConSole mounting system designed by manufacturer Renusol remains impeccably stable after 15 years of use. This is the conclusion of the test report drawn up by the renowned Kunststoff-Institut Lüdenscheid, which found that exposure to sunlight has not caused any brittleness... Continue reading >> Posted by Gisela Bühl | 2013-07-04 1,600 keynote, plenary, oral and visual presentations during EU PVSEC 2013 The detailed Conference Programme of the 28th European Photovoltaic Solar Energy Conference and Exhibition (EU PVSEC) is available, featuring more than 1,600 Keynote, Plenary, Oral and Visual Presentations. The EU PVSEC 2013 will take place from 30 September to 04 October 2013 at Parc... Continue reading >> Posted by Gisela Bühl | 2013-07-03 Three new solar parks in Romania with a total capacity of 9MW The three solar parks are located approximately 360 km northwest of Bucharest and built on almost 19 hectares overall. Just six weeks after the start of construction all three solar parks have been completed. These investments are supported through the Romanian promotion... Continue reading >> Share this! First page | Last page | Previous | 11 1213 | Next Activity: 4 users connected Tags Cloud India Energy News Solar Energy Directory Energy companies guide Alternative Energy News Latest Interviews International Energy Companies Guide International Magazines Spanish Renewable Energy News Homepage Magazines Enewsletters Articles Interviews Companies Guide Advertising Agenda


text:
Our TeamClose-knit. Passionate. Dedicated to your success.
Dany Frongia
Artist + Illustrator
Hi, my name is Dany (aka Cais). I was born in Cagliari, Italy, in 1979, and I currently live in London, UK, where I work as a cover artist and book illustrator.
By the age of four, I was already showing a passion and talent for drawing, inspired by the colorful style of Disney classics and later manga.
So I studied and obtained a degree from art school, then dedicated myself to mastering airbrush techniques on bikes before shifting my focus to digital graphics.
My first art exhibitions on canvas occurred in the diverse galleries of London when I moved here in 2009.
In 2010, I made the decision to dedicate myself to illustrating books; I now collaborate with authors and publishers from all around the world!


text: Lockwood 1220 Series Brass Round Rose Door Handles 53mm round rose, 27 lever styles, high quality solid brass. Lockwood 1220 Symphony Series door furniture is manufactured from high quality solid brass material. The comprehensive lever range matched with concealed screw fixings by way of threaded rose trims, provides a stylish look for the most elegant interiors. Proudly Australian Made at our factory in Oakleigh to the highest quality standards for strength, durability and corrosion resistance. Lever 3253mm Rose. Lever 41 - Intermezzo53mm Rose. Lever 44 - Arpeggio53mm Rose. Lever 45 - Sontana53mm Rose. Lever 53 - Veloce53mm Rose. Lever 5553mm Rose. Lever 55A53mm Rose. Lever 59 - Overture53mm Rose, AS1428.1 Compliant, Lever 6053mm Rose. Lever 6153mm Rose. Lever 6553mm Rose. Lever 6653mm Rose. Lever 6753mm Rose. Lever 7053mm Rose, AS1428.1 Compliant. Lever 71 - Tempo53mm Rose. Lever 74 - Ving53mm Rose, AS1428.1 Compliant. Lever 7653mm Rose, AS1428.1 Compliant. Lever 7753mm Rose, AS1428.1 Compliant. Lever 78 - Cadenza53mm Rose. Lever 79 - Tenor53mm Rose. Lever 79B53mm Rose. Lever 8053mm Rose, AS1428.1 Compliant. Lever 8353mm Rose. Lever 8553mm Rose, AS1428.1 Compliant. Lever 9053mm Rose, AS1428.1 Compliant. Lever 9253mm Rose, AS1428.1 Compliant. Lever 97 - Chorus Line53mm Rose. What makes Brass so good? Still Australian designed and made, the Lockwood range has adapted as design trends have come and gone but one thing has remained constant - the high quality brass used to make it. Whether it is for aesthetics, ergonomics, functionality or durability brass remains the ideal material for high quality door furniture. Brass is highly durableBrass has a low friction surface which makes it ideal for connected moving parts. This is why it is the perfect choice for producing high use door furniture that will prove durable with minimal servicing. Lockwood brass door furniture has been successfully tested to exceed the highest durability rating (D8, 500,000 cycles) under the Australian Standard (AS4145.2: 2008). Brass is corrosion resistantBrass door furniture provides durable performance in high corrosion applications. Unlike other commonly used materials it contains no iron so it will not rust or tea stain in high corrosion environments. Lockwood Brass Door Furniture in satin chrome brushed finish (SC) has been successfully tested under NATA conditions to maintain both function and finish under prolonged neutral salt spray test for over 1000 hours satisfying the highest ranking (C10) of the appropriate Australian Standard (AS4145.2: 2008). This result confirms that Lockwood Brass Door Furniture the ideal choice for use in coastal applications and other corrosive environments. Brass is greenBrass is a highly machinable material making it able to be accurately manufactured with less scrap, less rework and less energy than other materials. Products made from brass generally have good "cradle-to-grave" characteristics as not only do they show good durability but brass is also readily recycled at the end of the products working life. Furthermore Lockwood Brass Door Furniture is manufactured right here in Australia so there is far less energy expended shipping product into the country and the manufacture occurs at ASSA ABLOY Australia's ISO 14001 accredited manufacturing facility.


text:
Catit Scratcher with Catnip; Available in 2 sizes
Online Price $5.47Regular Price $6.97
This variant is currently sold out
A cat's need to scratch is instinctive. It helps them to sharpen and remove the dead outer layer of their claws, stretch and flex their bodies and work off energy. The Catit Scratching Board with Catnip provides your cat with a corrugated scratching surface, while helping to protect your furniture from claw damage.


text:
Question: Calculate the price of a 5 year 1 000 par value bond
Calculate the price of a 5-year, $1,000 par value bond that makes semiannual payments, has a coupon rate of 8 %, and offers a yield to maturity of 7 %. Recalculate the price assuming a 9 % YTM. What is the general relationship that this problem illustrates?
View Solution:
View Solution:
Answer to relevant QuestionsA $1,000 par value bond makes annual interest payment of $75. If it offers a yield to maturity of 7.5 %, what is the price of the bond? A bond makes annual interest payments of $75. The bond matures in 4 years, has a par value of $1,000, and sells for $975.30. What is the bond's yield to maturity (YTM)? What is the price of a zero-coupon bond that has a par value of $1,000? The bond matures in thirty years and offers a yield to maturity of 4.5 %. Calculate the price one year later when the bond has twenty-nine years left ...Why is it not surprising to learn that growth rates rarely show predictable trends? Hill Propane Distributors sells propane gas throughout the eastern half of the state of Texas. Because of population growth and a construction boom in recent years, the company has prospered and expects to continue to do ...
Post your question


text: Assam Police Recruitment is for filling up of 346 existing vacancies in the rank of Sub-Inspector of Police (UB) (including 62 SI (UB) exclusively for Special Branch) in the pay scale of Rs. 5200-20200 (Pay Band No. 2) plus Rs. 3300 grade pay plus other allowances as admissible under the rules and … [Read more...]


text:
AC Projects presents Mana, A new film by Eric Minh Swenson
Andi Campognone, Director of AC Projects and Eric Minh Swenson, Founder of EMS Productions announce the making of a documentary film on southern California artists who share the skill and affinity of surfing and how their love of, and interactions with the dynamics of the ocean inform their artwork. Each artist approaches their work differently in their process, mediums and styles, yet they all share a reverence for the power, beauty and complexity of the ocean. They are additionally unified by their strong community and family connections, each with a commitment to younger generations through art and surfing.
The documentary will be shaped by the directorial vision of Los Angeles-based filmmaker Eric Minh Swenson, who has produced over 120 films featuring major LA artists, curators and collectors. Celebrated cinematographers Marcel Morin and Sarah Mueller of Vitae Sessions and renowned curator and art champion Andi Campognone will compliment Swenson's aesthetic oeuvre. Mr. Swenson's team will craft a feature length film focusing on the brotherhood of a group of artists selected for their contributions as modern day pioneers of the southern California art world, each working on their own terms within the light and space, finish fetish, design and assemblage movements that have come to shape and define the Los Angeles art scene. As divergent as each artist's work is in comparison, they all share a common thread in their process and vision and are constantly driven by the influences and forces of family, friendships, stoke, aloha and the common bond of the unseen mana (power) of the land and sea.
Their interaction and conversation with each other and the environment will be the focus of Swenson's, Morin/Mueller's and Campognone's visual narrative. Filming will take place within the first two weeks of July 2013 and center around the Kailua-Kona side of the Big Island with excursions to significant ceremonial and surf sites around the island. Shooting in the spirit of Terrance Malick and Werner Herzog, the film will convey a serene, meditative mood where Zen philosophy, art principles, bravery and humility form a cohesive narrative of what will undoubtedly become one of the most ambitious and celebrated films created on Southern California art, surf culture and history. The film will also be débuted and screened in coordination with a major Los Angeles museum exhibition featuring the art of these eleven influential artists.
For more info on Eric Minh Swenson or project inquiries visit his website : thuvanarts.com
ART FILM SERIES: thuvanarts.com/take1
MUSIC VIDEOS: thuvanarts.com/musicvideos


text:
The two arch-rivals will take on each other tomorrow at the Pindi Cricket Stadium.
India restricted England to 209 for four in the 40-over-a-side match after winning the toss. In reply, the Indians reached the target in the 27th over with six wickets in hand.
Subhash Boya was the top-scorer for the Indians with his unbeaten knock of 88. Man-of-the-match Ashish Nagi also chipped in with fine half-century after effecting two run outs during the England innings as India cruised into the final.
Earlier, in the first semi-final, Pakistan had thrashed Australia by 10 wickets to sail into the final. The defending champions will hold the edge going into the title clash as they have already beaten India in one of the group matches.


text:
Written by renowned experts in the field, this book assesses the status of groundwater models and defines models and modeling needs in the 21st century. It reviews the state of the art in model development and application in regional groundwater management, unsaturated flow/multiphase flow and transport, island modeling, biological and virus transport, and fracture flow. Both deterministic and stochastic aspects of unsaturated flow and transport are covered. The book also introduces a unique assessment of models as analysis and management tools for groundwater resources. Topics covered include model vs. data uncertainty, accuracy of the dispersion/convection equation, protocols for model testing and validation, post-audit studies, and applying models to karst aquifers.
There are currently no reviews for this product. Be the first to review this product!


text:
Ham and Swiss Tomato Bites
Be the first to review
READY IN: 25mins
Recipe by Redneck Epicurean
These are tasty appetizers and look so good on a serving tray. They are geared more toward adult tastes, but you might be surprised to find your kids wanting to try them. The sun-dried tomato pesto is a great alternative to the every-day pizza sauce.
See Discussion:
Ingredients Nutrition
- 1 (13 ounce) canrefrigerated pizza dough
- 3⁄4 cup shredded gruyere or 3⁄4 cup swiss cheese
- 1 tablespoon dried parsley flakes
- 1 lb deli ham
- 1⁄3 cup sun-dried tomato pesto
Directions See How It's Made
- Preheat the oven to 400 degrees. Spray a mini muffin pan.
- Chop the ham and combine with the pesto, cheese, and parsley.
- On a lightly floured board, unroll the dough. Roll into a 12x15 rectangle. Cut 20 3-inch squares from the dough. Press into the muffin cups, flaring the corners (this looks so pretty!).
- Divide the filling into the cups.
- Bake 10 minutes or until the crust is just browned.


text:
by Tim McMahan
(Hermann, MO, USA)
I have been flying RC airplanes for 3 years, designing my own for 2. Suddenly, I got the urge to do a kite. Can you offer any advice? I can gladly throw you a bone on our YouTube channel as well. Perhaps we can help each other that way.
I edited your title to read 'Radio Control Kites', in case you were intending to do one of those. As opposed to the standard tethered variety! While never having made or flown RC kites myself, I know there are some highly refined motor units available for powering kite-like craft. ARF Vector Power Units they are called, since you control the thrust-line of the motor in 2 axes for much more than just directional control!
Over at Amazon, I notice that they are offering some kites from Premier, like the VR Delta Box RC Kite which are 'Vector-Ready' or VR for short. It looks like they are ready to take the motor near the center of gravity of the kite. It strikes me that these kites might be particularly suitable for copying (the concept, non-commercially!) and doing variations for your own personal use.
Perhaps you could get some estimate of the weight and wing area of a VR Delta Box at Amazon, and then do a keel-less Delta with similar specs. Mount the motor under the vertical spar, with sturdy skids to protect it from ground contact. I know my Deltas double as gliders when the line goes slack! With no keel, and a bit of sail billow for directional stability, I can imagine it working quite well. Slow and graceful! First tests at 1/4 throttle perhaps, doing extended glides to the ground.
Now, if you actually just wanted to do a decent ordinary kite, perhaps you could look at the Dowel Rokkaku first. When bored with that, move on to the Dowel Dopero. Both of these are strictly for light-to-moderate winds, and both go straight overhead in thermals!
Checked out the movie at your YouTube channel - it makes me keener to start taking footage from my kites :-) If you want to link, why not link to one of my RC Kites pages. Thanks!
Join in and write your own page! It's easy to do. How? Simply click here to return to About Kites.
This printable e-book takes you step-by-step through making a 119 cm (4 ft) wide Parachute kite. It's not quite that wide in the air since the canopy takes on a distinct curved shape when inflated. This 14-cell kite performs best in moderate to fresh wind speeds. That's 20 to 38 kph or 13 to 24 mph. In gentle winds, this kite will hang in the air at fairly low line angles. In fresh winds, it pulls firmly for it's size, so small kids should only fly it while supervised!
Every kite design in
the MBK Soft Series satisfies the following points...
For the greatest chance of success, I make recommendations regarding the materials. For example, the type/weight of plastic, type/width of tape and line type/strength. Close enough should nearly always be good enough, since the design is well-tested and should be tolerant of small differences from my original.
Get the e-book for making the MBK Parachute kite. After making your first one in plastic and seeing how it performs, you can try soft Tyvek or rip-stop nylon for your next build.
The e-book is a PDF file - which means printable instructions to refer to while you make the kite. It also means convenient off-line access if that suits you better.
Aug 16, 17 06:00 AM
This previously published page is full of general info on this type of kite, including some history. With a video clip and a good photo, it's worth checking out...
This one's FREE
Download it now!
"Love the easy to understand step by step instructions, made from next to nothing materials and above all so much fun to fly... cheers Tim for sharing your well thought out pdf kite designs with the whole world.
Very satisfying making your own and watching them get air-born for the first time."
"I decided to run kite making as an elective again on this camp in the past week - so I bought all your e-books, a bunch of materials, and then took a group of 10 high school students through making the kites over 4 days. We built a diamond, a Barn Door, a Delta, and two skew delta kites. Again - every single kite flew."
"I've just bought your super e-book and spent most of last night pouring through all the great stuff in it!
Very detailed and USEFUL information - thanks for such a great book."
years ago, I tried making a kite using the 'instructions' in a free
kite-safety booklet. What a disappointment for a young boy.
Your instructions and methods are wonderful. You help the builder to focus on accuracy, without making it hard. Also, you use materials that are durable, yet cheap!"
"omg i made a kite from this site and i fly it ....... booom i didnt expect this bc in the other sites instuction are trash
thank you"
This one's FREE
Download it now!
Wind Speeds
Light air
1-5 km/h
1-3 mph
1-3 knots
Beaufort 1
Light breeze
6–11 km/h
4–7 mph
4–6 knots
Beaufort 2
Gentle breeze
12–19 km/h
8–12 mph
7–10 knots
Beaufort 3
Moderate breeze
20–28 km/h
13–18 mph
11–16 knots
Beaufort 4
Fresh breeze
29–38 km/h
19–24 mph
17–21 knots
Beaufort 5
Strong breeze
39–49 km/h
25–31 mph
22–27 knots
Beaufort 6
High Wind
50-61 km/h
32-38 mph
28-33 knots
Beaufort 7


text:
Customer Service Supervisor – Solon, OH
Job Overview:
Under the direct supervision of the Manager of Customer Service, the Supervisor will coordinate, organize, distribute, and verify the work of other participants in their training and day to day activities. Act as a resource for all other Customer Service team members.
- Coordinates and assists with directing the Customer Service Team
- Interacts with customers providing information on inquiries, products, accounts, and services
- Ensures prompt response and efficient use of unit's resources
- Participates in prepare sales equipment placing orders and restocking as necessary
- Performs administrative duties appropriate for the activities of the department
- Directs and assists Customer Service Representatives with investigation of customer service complaints managing escalated complaints as necessary
- Coaches and trains team members using corrective action and Performance Improvement Plans as necessary
- Communicates solutions, success, and opportunities to the Customer Service Manager
- Updates departmental dashboards and maintains team performance metrics
- Assists in conducing employee performance reviews
- Other duties as assigned
- Minimum 3-5 years' experience in a customer service position
- Prior leadership over a customer service team strongly preferred
- Ability to coach and train other team members
- Previous experience executing performance improvement plans and corrective action a plus
- Experience managing performance metrics and performance reviews for team members
- Strong prioritization skills with the ability to manage multiple competing tasks
- Ability to make quick decisions and execute solutions in an effective manner
- Prior experience making departmental suggestions for improvement
- Proven ability to utilize an ERP system (QAD or Epicor Vantage preferred)
To apply, please send your resume to firstname.lastname@example.com


text:
View the rest of your items by clicking on the link below
Average Review:
Find out how much of this scent to use
with our
Fragrance Calculator
Spiced Amber Ale Fragrance Oil: This ale inspired fragrance is out of this world! The fragrance starts with a fresh citrus top note and has a warm, exotic finish. The base is a wonderful synergy of pine, clove, honey and vanilla. Preformance In Cold Process Soap: This fragrance doesn't accelerate trace or discolor in cold process soap making
Flashpoint: 200ºF+This fragrance oil is phthalate free
Photo Attribution: © Can Stock Photo
Coupled with a spiced amber ale beer as the liquid in my HP soap and poured into a mustache mold, this scent is great! I get requests for it all the time!
I used this in my beer soap and although it behaved well in my soap I tried to sell it two different festivals for 3 days in a popular cowboy town of Oregon that is full on "all about horses and beer" due to the large amount of micro breweries we have in the area. After 400-500 people smelled it, I managed to sell 5 bars and am stuck with not only the other 14 bars from my batch, I have another 4 oz. bottle that will probably sit for a long time to come. If you're looking for great beer fragrances, I sold out of both the honey ale and the oatmeal stout in both shows. It has a masculine-y aftershave scent that actually made me as well as a few customers taste it.
Kelsey from Bramble Berry replies...Hi Tamara! I'm sorry this scent wasn't you and your customers' favorite. We love the this ale-inspired blend with fresh citrus and rounded out with warm honey and vanilla. I'm glad you like our Honey Ale and Oatmeal Stout Fragrance Oils! If you're looking for another beer scent you may like Raspberry Porter Fragrance Oil.
The men in my family love this scent! It plays nice in cold process soap too :)
This does not remind me of a beer scent at all. I personally find it unpleasant. That being said, it behaved well in my soap and it smells the same out of the bottle as it does in the soap after several days. Only time will tell if it changes. Maybe it will be for the better.
Oh my goodness!!! We love this fragrance oil!! My husband showered with it last night and he LOVED it!! And I loved the way it smelled on him!!! I am odering more for sure. This is a favorite for sure!!!!
We're a friendly group who love social media. See you 'round the web!


text:
As speculated TDP senior leader and former minister K Vijayarama Rao was preparing to join the ruling TRS party.
Vijayarama Rao, who was a former director of CBI before entering politics, today said he is likely to meet Chief Minister K Chandrasekhar Rao in a day or two. Meanwhile, TRS minister KTR today went to the residence of Vijayarama Rao and met him. Later he told the media that Vijayarama Rao said he would be happy to involve himself in the development of the State.
After calling on former director of CBI, KTR said democracy would be strengthened if educationists join politics. It is learnt that Vijayarama Rao has sent his resignation letter to TDP on Friday. He sent his resignation letter to TDP head office by fax. (NSS)


text:
Please wait a few seconds while your cart is being loaded.
Login to see membership pricing and/or to see items you may have added using another computer or device
Renew Your Membership
Member Library
TD Magazine
Member Directory
The Buzz E-Newsletter
ATD Links E-Newsletter
Watch & Learn Webcasts
Job Bank
State of the Industry Report
ATD Buyer's Guide
Learning Executives Confidence Index
Young Professionals
Chapter Locator
Chapter Leader Community
Power Member
Join ATD and gain immediate access to the talent development research, news, and best practices you need to take your career—and your organization—to the next level.
Access your ATD member benefits in one convenient location.
Join ATD or renew your membership today.
Training and Training Basics
Instructional Design
Business and Management
Career Development
Measurement, Evaluation, and ROI
Organization Development
Workplace Issues
Series Titles
ASTD Handbooks
Search All Books
Current Issue
Search Issues
All Reports
Talent Development Executive Confidence Index (TDXCI)
The Public Manager
ATD LINKS E-Newsletter
Community of Practice Newsletters
ATD Blog
Community of Practice Blogs
Never stop learning with OpenBook.
Talent development delivered – get 12 single-topic issues a year!
ATD International Conference & EXPO
ATD-Yale Foundations of Management Excellence
Core 4 Conference
Chapter Leaders Conference
Chapter Regional Conference
Learn From the BEST
Healthcare Summit
Talent Next
Asia Pacific Conference
China Summit
European Summit
Japan Summit
Korea Summit
Latin American Summit
Middle East Conference & Exhibition
LearnNow: Design for Behavior Change
LearnNow: Emotional Intelligence
LearnNow: Game Design
LearnNow: Getting Started with AR and VR
LearnNow: New Employee Onboarding
LearnNow: The Neuroscience of Learning
LearnNow: Designing for the Modern Learner
LearnNow: Flipped Classroom
LearnNow: Change Management
LearnNow: Design Thinking
ATD's Core 4 Conference will provide you with the most practical, fundamental knowledge you need to effectively develop learners. You'll acquire a foundation for talent development, and create better learning experiences and improved performance outcomes. Hurry and get this great price on your registration.
Register Now
The LearnNow: Developing the High-Performance Manager workshop utilizes the ACCEL framework to teach managers the fundamentals of effective leadership, including accountability, communication, collaboration, engagement, and listening and assessing.
The LearnNow: Design Thinking workshop will show you how to shift to a human-centered instructional design approach by leveraging the tools and techniques found in the discipline of product design.
Fundamental Skills
For the Trainer
For the Instructional Designer
For the Manager
For the HR/OD Professional
Learning Roadmap
ATD Education
The ATD Competency Model
Our Facilitators
Rates & Pricing
Request a Catalog
Subscribe to Our E-Newsletter
All Courses
Browse the 2017 e-catalog
Online Courses
On Demand
Essentials Series
Face-to-Face Courses
ATD Expert Coach™
ATD Master Instructional Designer™
ATD Master Performance Consultant™
ATD Master Trainer™
CPLP Preparation Courses
Bring Training to Your Team
Team Skills Gap Assessment
Course Licensing
Registered for an education program? Get started by logging in to the Learning Portal to get your course materials.
Log In
Browse the ATD Education Spring/Summer 2017 e-catalog for program dates and locations.
Want unlimited access to our entire portfolio of online workshops? Become an Essentials Series Annual Pass holder.
Practice Exam (pCPLP)
Preparing for the CPLP: Interactive Guide
Apply and Manage Records
Testing Fees and Locations
Test Schedule
International Applicants
Get a step by step overview of the CPLP process, which includes two assessment tools.
Learn More
Learn more about which workshops ATD offers to prepare.
Get started with ATD's Learning System—the official resource for CPLP study.
Global HRD
Human Capital
Learning & Development
Learning Technologies
Sales Enablement
Science of Learning
Senior Leaders & Executives
Career Development Blog
Global HRD Blog
Government Blog
Healthcare Blog
Human Capital Blog
L&D Blog
Learning Technologies Blog
Management Community Blog
Sales Enablement Blog
Science of Learning Blog
Senior Leaders & Executives Blog
Each community focuses on a key area of the talent development field and is led by a community manager whose in-depth knowledge will ensure that the content, offerings, and resources are consistent with your needs.
Get Started
ATD's Core 4 Conference will provide you with the most practical, fundamental knowledge you need to effectively develop learners.
Browse the ATD Education Spring/Summer 2017
e-catalog for program dates and locations.
Training Delivery
Enterprise Learning Plan
Forum Benefits
Forum Member Organizations
Forum Member Website
We bring Education programs to you, specifically tailored to your organization's needs and business goals.
Contact an Enterprise team member today and we'll find a solution to fit your needs!
Provide your team with access to ATD's premium content all in one place.
Upcoming Webcasts
Archived Webcasts
Find a Job
Post a Job
Jobs at ATD
BEST Awards
Excellence in Practice
Browse Research Reports
Talent Development Executive Confidence Index (TDXCI)
Deliver engaging and effective training. Become a Master Trainer.
This free app puts over 20 activities all in the palm of your hand.
U.S. Conferences
International Events
LearnNow Workshops
Search All ATD Publications
It is more important now than ever for HR professionals to reexamine their recruitment, onboarding, and retention strategies. Join us for TalentNext: Building an Engaged Workforce, November 7-8 in West Palm Beach, Florida, to learn practical strategies you can apply immediately to increase engagement levels, spark innovation, and attract and retain high performers.
Register Today!
It's Your Profession. OWN IT!
Join ATD or extend your membership.
To view or add items to your Wish List, please log in.
Not yet an ATD registered user? Click here to register.
Already registered? Click here to log in.
Most of us are familiar with Gallup's research on engagement, referred to as Q12, which presents 12 actions that can be implemented to achieve higher levels of employee engagement. This article focuses on the concept of flow. Flow is an additional precursor—or subset—of engagement. We will demonstrate how human capital practitioners can contribute to the level of employee engagement in their organizations by simply setting the stage for flow to occur more often.
Flow: A subjective psychological state that occurs when your signature strengths and greatest talents converge, enabling you to become completely absorbed in the activity at hand.
The experience of flow
What is the experience of flow like? When we enter a flow state we are so engaged in the task at hand that
This particular subset of engagement is one of many aspects that collectively contribute to organizational well-being. Because achieving flow involves relying on signature strengths to accomplish meaningful or pleasurable tasks, expecting to attain flow in every aspect of work would lead to disappointment. ("I am a creative genius who produces exquisitely compelling material for new ad campaigns, and this new manager re-assigns me to the finance department? I will never flow again.") We can, however, elicit more frequent occurrences of workplace flow by implementing some fairly simple strategies.
Relating to flow
To better illustrate the flow experience, let's look at some examples. Flow often results from intellectual activities, such as a participating in a problem-solving conversation at work, commanding the room during a sales presentation, or even reading a bestseller. Other ways we enter flow revolve around social experiences, such as working on an interesting group project, rallying with others to achieve team quotas, or even getting caught up in a night of dancing and stimulating conversation with friends. We also get to a flow state when the body and brain "team up" in an exciting and engaging physical challenge. In truth, many activities can produce a state of flow. These examples serve to highlight flow as a positive experience, which brings with it feelings of joy.
How to encourage flow as a tool for enhancing engagement
Identify and consciously use signature strengths—flow happens when we use our strengths. Knowing our strengths is unfortunately just not enough. Look for opportunities and assignments that leverage and build on the talents that come naturally to you or your employees. The Institute on Character has a terrific free signature strengths assessment that can help you get started. Or, check out Strengthscope's 360-degree or team strengths assessment.
Start by tackling a Goldilocks task—not too hard, and not too easy. If you are looking for flow, begin with a task or goal that feels "just right." Why? Because when the task or goal is too difficult, there's a risk of becoming frustrated; if the task is too easy, there's a risk of becoming bored. Either way, you may quit long before you reach a state of flow. Flow comes from consistently learning and increasing competency. If you are a manager, help employees find challenging but achievable tasks that build on their strengths, and then give them immediate, consistent, and constructive feedback that focuses on the effort they are putting into the assignment.
Remove distractions—focus is key to finding flow. Intentionally and purposefully find ways to limit interruptions and distractions for yourself and your employees. Reserve a block of time and make it multitasking-free. Work from home, book off-site meetings, or hide out in an isolated conference room. Turn off your phone (or at least the audible reminders). Don't expect instant communication between team members. Set expectations for communication-free hours. Honor weekends, lunch hours, and vacations. Meditate.
What are the benefits of flow in the workplace?
Flow is about being "in the zone." The more we are in the zone at work, the more productive, motivated, and inspired we remain. In addition, research indicates that inducing a state of flow helps to
The simplicity and importance of a positive psychology science
One of our objectives within these articles is to provide evidence-based, actionable strategies that—through their simplicity—promote optimal performance. Scientific minds around the world spend years conducting and then publishing research that has the ability to impact our lives greatly. Unfortunately, this research usually finds its way to some lonely psychological or behavioral journal, and there it stays.
Tal Ben-Shahar has off-handedly remarked that, on average, seven people read any given article printed in a psychological journal. (Even more disheartening is that one of the seven includes the researcher's mother.) As human capital professionals, we have a collective opportunity to capitalize on this important research by simply putting the findings to the best possible use. In other words, simple interventions can be great interventions—when we apply them.
For more on the positive workplace, read the full blog series.
Communities of Practice:
Human Capital
Patrick Howell combines 15 years of active organizational development experience with extensive research and study of optimal human performance, to help him succeed as Executive Director of the Institute for Advanced Human Performance, a collaborative learning initiative offering seminars and certification programs in positive psychology and coaching. Patrick also is President of Team Development Group, a boutique consulting firm he co-founded in 2004 with the clear focus of fostering strength-based, results-driven teams within public and private sector organizations. A leader in the field of organizational development and a recently appointed executive council member to Red Panamericana, an organization promoting Positive Organizational Scholarship throughout the Pan American region, he is considered a pioneer in the Positive Psychology Coaching movement. A former Director of Corporate Initiatives for Dale Carnegie Training, he is no stranger to the facilitation of large and intimate audiences alike. Patrick is the host of Career Corner TV, where he conducts interviews with various business leaders and he is authoring his first book on the topic of optimal performance and applied positive psychology; email@example.com.
Patrick Howell combines 15 years of active organizational development experience with extensive research and study of optimal human performance, to help him succeed as Executive Director of the Institute for Advanced Human Performance, a collaborative learning initiative offering seminars and certification programs in positive psychology and coaching. Patrick also is President of Team Development Group, a boutique consulting firm he co-founded in 2004 with the clear focus of fostering strength-based, results-driven teams within public and private sector organizations. A leader in the field of organizational development and a recently appointed executive council member to Red Panamericana, an organization promoting Positive Organizational Scholarship throughout the Pan American region, he is considered a pioneer in the Positive Psychology Coaching movement. A former Director of Corporate Initiatives for Dale Carnegie Training, he is no stranger to the facilitation of large and intimate audiences alike. Patrick is the host of Career Corner TV, where he conducts interviews with various business leaders and he is authoring his first book on the topic of optimal performance and applied positive psychology; firstname.lastname@example.com.
Kim Rowe, one of the founding partners of Agentive, has been an independent marketing and sales consultant to the medical and pharmaceutical industries since 1993. At Agentive, Kim provides clients with marketing and sales performance development expertise, including assessment, training, coaching, and project management. Kim was previously employed in sales, marketing, and training with ConvaTec, a Bristol-Myers Squibb company, and C.R. Bard. She is a board member of the Health Care Businesswomen's Association and an active member of ASTD and the New Jersey Association of Women Business Owners (NJAWBO). Kim speaks regularly on the topic of generational leadership as well as other leadership and management topics. She is on the Board of Directors of the Montgomery Friends of Open Space and was one of the founders of the MFOS Farmers Market in Montgomery Township, New Jersey.
ASTD changed its name to ATD to meet the growing needs of a dynamic, global profession.
Stay connected with:
ASTD is now the Association for Talent Development (ATD).
Phone, U.S. Only: 1.800.628.2783
Phone, International: 1.703.683.8100
Email: firstname.lastname@example.com
Fax: 1.703.683.1523
Please wait while we are getting your account information.
Please visit the Member Center page to ensure you still have available credits.
For assistance, please contact ATD Customer Care:


text:
America Reframed - By Blood
By Blood chronicles American Indians of African descent as they battle to regain their tribal citizenship. The film explores the impact of this battle, which has manifested into a broader conflict about race, identity, and the sovereign rights of indigenous people. The film demonstrates both sides...
Video Title


text:
A Leading Man
1hr 36 min | HD | 2014 (NEW!)
Genre: Drama
U.S. Theatrical Release: Sept 26, 2014
When a young and talented Chinese American actor is fired from a starring role on a television show, he attempts to salvage his career by entering into a romantic relationship with a successful casting director.
Everyone is happy for rising actor GQ Qi – the network, his mother, his best friend – everyone except GQ himself. He is stuck playing an offensive stereotype on a television sitcom, and the day he decides to speak up for himself on set, the executive producer fires him. Struggling to pick up the pieces, he starts dating A-list casting director Rachel. Love and work become intertwined.
Their relationship survives the protestations of GQ's mother and best friend, but starts to show strain as it becomes clear that GQ is unable to land another acting gig. As pressures from work, love and family come to a head, GQ must confront the hard question: How much of himself will he compromise for career success?
Jack Yang
Heather Mazur
Kate Miner
Directed By:
Steven J. Kung
Produced By:
Justin Bell
Jon Kondrath
Music By:
Benjamin Wynn
Jeremy Zuckerman
type: Film by: Mance Media


text:
This section contains 1,390 words
(approx. 4 pages at 400 words per page)
Eliza Naumann
When the narrative opens, Eliza Naumann is a fifth-grader at McKinley Elementary School. Eliza is a mediocre student who is unconvinced of her seeming mediocrity. Eliza does not have any close friends, but does not suffer as a result of this fact. Eliza spends a good deal of time watching re-runs on television and fantasizes that her life is, in fact, some sort of movie. Eliza's fantasies take the place of known realities and it is not until she wins the district spelling bee and sees a photograph of her family in a local newspaper that she realizes her family does not fit her internal picture.
Eliza is the daughter of Saul Naumann (a cantor) and Miriam Naumann (an attorney). She has an older brother, Aaron, whom she idolizes for a time. Eliza does not enjoy an especially close relationship with either of her parents, who are basically strangers to her. She is surprised and delighted at her father's offer to help her study, although she does her best to hide her enthusiasm from Saul, believing that it might cause Saul to change his mind.
Eliza's entire personal paradigm changes, however, with her discovery of the writings of Jewish mystic Abraham Abulafia. Spelling, for Eliza, is the entry point into communion with God and the realization of a higher purpose.
Saul Naumann
Saul Naumann spends the first seventeen or so years of his life as Sal Newman, the son of an auto mechanic. When he first discovers his Jewish heritage at the age of thirteen, Sal changes his name back to Saul and goes in search of God—or at least in search of expanded thinking and alternate ways to view the world. Saul turns his back on his father and embarks on a lifelong journey toward transcendence. After extensive experiences with LSD in college, Saul becomes interested in Kaballah, a form of Jewish mysticism. Study for its own sake and the pursuit of knowledge are most important to Saul Naumann.
Saul is married to Miriam, an attorney. Theirs is a marriage of comfort and order. Saul is completely unaware that Miriam is a kleptomaniac. The Naumanns have two children, Aaron and Eliza (whom Saul refers to as "Elly-belly"). Saul, however, sacrifices deeper closeness with his family for his studies of the Torah and Kaballah. It is Saul who is closer to the children when they are younger, especially Aaron, with whom Saul plays and practices guitar. When she wins the district spelling bee, though, Saul notices something special about his daughter and decides that her path and his are intertwined. It is for this reason that Saul begins tutoring his daughter in the concepts and principles developed by Abraham Abulafia.
Miriam Naumann
Miriam (Grossman) Naumann is Saul Naumann's wife and the mother of Eliza and Aaron. Miriam is an only child whose wealthy parents are both killed by an automobile while they are out for a walk. She is an obsessive-compulsive kleptomaniac and a rabid perfectionist who is unable to form deep attachments to other people. Miriam's most profound relationships are with objects. Miriam's external locus of control is solidified the first time she experiences "Perfectimundo." She views her kleptomania not as stealing, but as a way to bring together the missing parts of herself. Taking things that do not belong to her is Miriam's way of establishing order in the world. Her fragmentation prompts Miriam to steal and then arrange the stolen goods in a storage space, which she calls her kaleidoscope.
Miriam is not close to either of her children or to Saul, for that matter. She sees Aaron as Saul's son primarily and she is at a loss as to how to relate to Eliza. Much like the kaleidoscope that is revealed later in the narrative, Eliza "generally equates the inside of her mother's head with the grand finale of a July Fourth fireworks display" (p. 17). Miriam is extremely intelligent and extremely eccentric.
Aaron Naumann
Aaron Naumann is the only son and oldest child of Miriam and Saul Naumann. For a time, Aaron fantasizes about becoming a rabbi. Aaron is highly intelligent, having been selected for the TAG (Talented and Gifted) program when he was Eliza's age. Aaron does not have close school friends and is bullied as a young child. Aaron and Eliza spend a good deal of time together before Aaron enters adolescence. Aaron does not know it, but he is Eliza's hero until she sees him being beaten up by a group of boys. Like his sister, Aaron Naumann entertains extensive fantasies. Aaron, however, daydreams about being popular, athletic, and talented.
Aaron Naumann, like his father, is a seeker. He prays diligently for God to reveal Himself. When his prayers are not answered, Aaron becomes disillusioned with his Jewish faith and he becomes interested in Krishna consciousness. When he begins spending time at the ISKCON temple, Aaron Naumann comes into his own as someone who is spiritually alive. While his attempts to explain Hare Krishna concepts to his father and sister fall flat, Aaron is convinced that Chali and the others at the ISKCON temple have found "the answer."
The only time Aaron Naumann ever sees his paternal grandfather, Heimel Naumann, his grandfather is lying in an open coffin.
Heimel Naumann (Henry Newman)
Heimel Naumann is born into a Jewish Orthodox family.
When Yehuda Naumann, Heimel's father, declares Heimel's fiancee Lisa as "not Jewish enough," Heimel and Lisa elope anyway (p. 10). Yehuda Naumann ignores the birth of his grandson, Saul (who becomes Sal), after which Heimel Naumann changes his name to Henry (Hank) Newman and turns his back on Judaism altogether. Hank works as an automobile mechanic and has hopes that Saul will follow in his footsteps. Saul is Hank and Lisa Newman's only child. "When Saul uses his student status to stay out of Vietnam, Henry officially washes his hands of his ungrateful, hippie Jew of a son" (p. 11).
Henry and Saul never resolve their differences.
Lisa Naumann
Lisa Naumann (later, Newman) is the mother of Saul Naumann and the wife of the former Heimel Naumann. Lisa introduces Saul to Judaism when Saul is thirteen years old. It is Lisa who instills a sense of religious and ethnic pride in her son. Lisa sneaks Saul to synagogue to worship when her husband Hank is out of the house. Lisa Naumann dies of cancer when Saul is fifteen years old.
Chali, whose real name is John, is a devotee of ISKCON (Hare Krishna) and a close friend of Aaron Naumann. Chali meets Aaron while Aaron is sitting in a park one day and he invites Aaron to the ISKCON temple. In terms of the narrative, Chali is to Aaron what Saul Naumann is to Eliza. Chali is Aaron's guide and tutor. Chali represents mysticism, and the search for communion with a Supreme Being.
Sinna Bhagudori
Sinna Bhagudori is one of the "smart girls" who attends McKinley Elementary School. Sinna is one of Eliza's competitors in the school spelling bee. Eventually, Sinna becomes a friend of sorts to Eliza Naumann. At the beginning of the narrative, Sinna is described as having "blue contact lenses and big boobs" (p. 7). Even though the other pupils at McKinley know that Sinna's eyes are not really blue, Sinna, who is obviously of East Asian descent, "insists that a lot of people's eyes change when they go through puberty" (p. 7).
Brad Fry
Brad Fry is another of Eliza's competitors in the school spelling bee. Brad is also classified as one of the "smart kids." Brad is described as having "a lot of moles" (p. 7). Brad is somewhat geeky, as evidenced by his presence at a summer camp for "kids who take math and science classes because they want to" (p. 7). Even though Brad tells the other kids at McKinley that he actually goes to soccer camp, no one believes this.
Rabbi Mayer
Rabbi Mayer is the spiritual leader of Temple Beth Amicha Synagogue. Mayer is a rather large man with a "broad forehead" and gray eyebrows. His eyes are quite small as if "to take in as little of the world as necessary" (p. 13). While Beth Amicha would not have been Mayer's first choice as a rabbinical assignment, Mayer made his choice based on the steady income offered by presiding over a suburban synagogue.
This section contains 1,390 words
(approx. 4 pages at 400 words per page)